What kisspeptin is
Kisspeptin is the collective name for a family of peptides cleaved from a single 145-amino-acid precursor encoded by the KISS1 gene. Proteolytic processing yields fragments of 54, 14, 13, and 10 amino acids, called kisspeptin-54, -14, -13, and -10. All four fragments share the same C-terminal decapeptide sequence and activate the same receptor, KISS1R, also known as GPR54.
The KISS1 gene was first identified in 1996 by researchers screening for genes that suppress melanoma metastasis, and the 54-amino-acid peptide product was originally named metastin for that reason. Its role as a hormone took another five years to surface. Ohtaki and colleagues isolated the peptide from human placenta in 2001 and identified it as the endogenous ligand for the orphan receptor GPR54 (Ohtaki T et al., Nature 2001;411:613-617). That paper turned a cancer-biology gene product into a signaling molecule with a receptor of its own.
Discovery and mechanism: KISS1, GPR54, and the reproductive axis
Kisspeptin's role in reproduction was not obvious from the 2001 paper. It came from genetics two years later. Two independent groups studying patients with isolated hypogonadotropic hypogonadism, a condition in which puberty fails to start and gonadotropin levels stay low, both traced the defect to loss-of-function mutations in GPR54.
Seminara and colleagues reported the finding in the New England Journal of Medicine in 2003, describing GPR54 mutations across several affected families and establishing that signaling through this receptor is required for pubertal onset in humans (Seminara SB et al., NEJM 2003;349:1614-1627). The same year, de Roux and colleagues published an independent case: a large consanguineous family with five affected siblings carrying a homozygous GPR54 mutation, in the Proceedings of the National Academy of Sciences (de Roux N et al., PNAS 2003;100:10972-10976). Mouse knockout studies published shortly after reproduced the same phenotype: animals lacking a functional Kiss1 or Gpr54 gene failed to undergo normal sexual maturation.
Mechanistically, kisspeptin neurons in the hypothalamus, concentrated in the arcuate nucleus and the anteroventral periventricular area, release kisspeptin onto GnRH neurons, which express KISS1R. Kisspeptin binding triggers GnRH release, which drives pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This kisspeptin-GnRH-LH/FSH chain sits upstream of the hypothalamic-pituitary-gonadal system that regulates puberty, the menstrual cycle, and fertility.
KNDy neurons: the GnRH pulse generator and metabolic integration
A specific subset of arcuate nucleus neurons, termed KNDy neurons for co-expressing kisspeptin, neurokinin B, and dynorphin, functions as the pulse generator behind intermittent GnRH release (Lehman MN, Coolen LM, Goodman RL, Endocrinology 2010;151:3479-3489). In this model, neurokinin B acts as a start signal within the KNDy network and dynorphin as a stop signal, together timing the pulsatile bursts of kisspeptin that reach GnRH neuron terminals in the median eminence.
KNDy neurons also carry receptors for leptin, insulin, and the gonadal steroids estrogen, progesterone, and testosterone, which places them at a junction between nutritional status and reproductive signaling. This is one reason why sustained caloric restriction or very low body fat can suppress the reproductive axis: energy-sensing hormones acting on KNDy neurons reduce kisspeptin pulse frequency, which in turn lowers GnRH and gonadotropin output. The KNDy model, built mostly from rodent and sheep studies, is part of why hypothalamic amenorrhea and some forms of functional hypogonadism are now investigated as disorders of kisspeptin pulse signaling rather than purely nutritional conditions.
Sexual dimorphism in human dosing studies
Human physiology studies through the 2000s and 2010s, mostly from the Imperial College London group led by Waljit Dhillo, measured how exogenous kisspeptin affects LH release in healthy volunteers. Men and women did not respond the same way.
Jayasena and colleagues administered kisspeptin-10 to healthy men and women and measured the LH response (Jayasena CN et al., JCEM 2011;96:E1963-E1972). In men, doses as low as 0.3 nmol/kg given by intravenous bolus produced a measurable LH rise, with the maximal response around 10 nmol/kg. In women tested during the early follicular phase, the same peptide, given as an intravenous bolus, a subcutaneous bolus, or a 90-minute infusion, produced no detectable LH response at comparable doses. The same women did respond when kisspeptin was given during the preovulatory phase of the cycle, when circulating estrogen is high. Kisspeptin sensitivity in women tracks the menstrual cycle stage; men stay consistently responsive.
A separate trial compared kisspeptin-10, kisspeptin-54, and GnRH directly in healthy men and found that GnRH produced a larger gonadotropin response than either kisspeptin isoform at the doses tested. GnRH remains the more potent direct secretagogue even though kisspeptin sits upstream of it in the signaling chain.
Clinical trials: IVF triggering and sexual desire disorders
The clearest translational application to date is triggering oocyte maturation during IVF in women at risk of ovarian hyperstimulation syndrome (OHSS), a complication that standard hCG triggers can cause. Abbara, Dhillo, and colleagues ran a phase 2, open-label, dose-finding trial of kisspeptin-54 in 60 women at high risk of OHSS at Hammersmith Hospital, London, using an adaptive dose design across four groups: 3.2 nmol/kg (n=5), 6.4 nmol/kg (n=20), 9.6 nmol/kg (n=15), and 12.8 nmol/kg (n=20) (Abbara A et al., JCEM 2015;100:3322-3331). Across all dose groups combined, live birth rate per embryo transfer was 45 percent. At the 9.6 nmol/kg dose specifically, live birth rate reached 62 percent. No patient in the trial developed moderate, severe, or critical OHSS.
More recently, the same Imperial College group tested kisspeptin in a different indication: hypoactive sexual desire disorder (HSDD). In a randomized clinical trial of 37 men with HSDD, of whom 32 completed the protocol, Mills and colleagues measured brain activity and penile tumescence responses to erotic stimuli after kisspeptin infusion versus placebo, published in JAMA Network Open in 2023 (Mills EG et al., JAMA Netw Open 2023). A companion trial tested kisspeptin in women with HSDD over the same period. Separately, a kisspeptin receptor agonist called MVT-602 has been tested in randomized, placebo-controlled trials in premenopausal women, with and without ovarian stimulation, as a longer-acting alternative to native kisspeptin for triggering the LH surge (Chan Y-M et al., 2023).
Kisspeptin research status and practical handling
Kisspeptin fragments arrive as lyophilized powder and require reconstitution before use in research protocols, following the same aseptic and cold-chain handling as other lyophilized research peptides. Kisspeptin-10, the shortest and most commonly used research fragment, has a molecular weight of approximately 1.3 kDa; the extra residues in the longer fragments change potency and half-life but not the core receptor-binding sequence. Storage at the recommended temperature and minimizing freeze-thaw cycles preserves a reconstituted solution; the lyophilized peptide storage guide covers temperature and humidity specifics relevant to shipping and storage in tropical conditions, and the dosing calculator covers concentration and volume math for preparing reconstituted stock.
The IVF trigger and HSDD applications remain investigational. Kisspeptin has not received regulatory approval for any human therapeutic use as of mid-2026. Sample sizes in the human dosing and clinical trials described above range from 37 to 60 participants, small by the standards of registration trials, and results have not yet been replicated in larger, multi-center studies. Research on kisspeptin analogues, including MVT-602, is aimed at improving on the short circulating half-life of native kisspeptin fragments, which is measured in minutes.